INTRODUCTION
Cerebral infarction is characterized by pan-necrosis in not only neurons but also glia and vascular elements [22]. At the cerebral hypoperfusion stage, the pathophysiology of cerebral infarction is related to primary anoxic-ischemic cell death and secondary neuronal injury.
Secondary neuronal injury is characterized by the activation of inf lammatory cytokines and production of free radicals, thereby leading to the production of potentially toxic materials and apoptotic cells [1,3]. Therefore, efficient removal of toxic and apoptotic materials is of primary importance for protecting the surrounding tissues from secondary neuronal injury [16].
Milk fat globule-epidermal growth factor VIII (MFG-E8) is a 66-kDa glycoprotein originally discovered in mouse milk and mammary epithelium. MFG-E8 was subsequently found to be widely distributed in various tissues in mice and other mammalian species, including humans [8,9,26].
MFG-E8, also known as lactadherin, has been demonstrated to act as an intermediary between apoptotic cells in the tissue and phagocytes, such as macrophages, and plays an important role in the inflammatory response and the clearance of apoptotic cells [25]. Notably, MFG-E8 has recently been recognized as a critical regulator of the inflammatory response, and many studies using various cell and animal models are investigating the potential role of MFG-E8 in secondary neuronal injury in cerebral infarction [5].
In acute cerebral infarction, therapies such as intravenous administration of recombinant tissue plasminogen activator within 4.5 hours and mechanical thrombectomy within 24 hours of stroke onset are widely used clinically [13]. However, after the acute phase of cerebral infarction there is no effective treatment other than supportive medication such as antiplatelet agents.
Therefore, we investigated whether MFG-E8 attenuates the cellular and biochemical toxic responses and enhances neuronal proliferation and angiogenesis after cerebral ischemia, and whether MFG-E8 ameliorates brain injury in the subacute stage of cerebral ischemia in a rat model.
MATERIALS AND METHODS
Animal model of ischemic stroke
All animal experiments were approved by the Institutional Review Board of the Korea University (Seoul, Korea; KUIACUC- 2016-0253) and were conducted in accordance with the National Institutes of Health Guide for the Care and Use of Laboratory Animals (National Institutes of Health [NIH] publication No. 80-23, revised in 1996). Adult male Sprague- Dawley rats (n=12), weighing 300-320 g (Orient Bio Inc., Seongnam, Korea), were used in this study.
Acute stroke was induced using the standard middle cerebral artery occlusion (MCAO) method, as previously described [2]. Animals were anesthetized with 5% isoflurane and were maintained under anesthesia with 1.5% isoflurane in a mixture of 70% N2O and 30% O2. After exposure of the common carotid artery, a 4-0 silicone-coated monofilament (Doccol Corp., Sharon, MA, USA) was inserted into the internal carotid artery to occlude the ipsilateral middle cerebral artery. The occlusion was maintained for 90 minutes, and the monofilament was subsequently removed. The animal was tested for spontaneous circling, and the tail-lifting test was also performed. In this experiment, 24 hours after onset of cerebral infarction was defined as subacute stage cerebral infarction.
Experimental groups
Twenty-four hours after MCAO reperfusion, animals were randomly assigned to one of the following two groups. Rats in the first group (n=6) were administered once recombinant human MFG-E8 (rhMFG-E8; R&D systems, Minneapolis, MN, USA; Catalog No., 2767-MF; 160 μg/kg/mL) intravenously via the tail vein, and those in the vehicle group were administered normal saline (n=6).
Neurobehavioral tests
Neurobehavioral functions were evaluated on days 1, 4, 8, 11, and 15 after MCAO using the modified Neurological Severity Score (mNSS) [4]. The mNSS is a composite of motor (muscle status and abnormal movement), sensory (visual, tactile, and proprioceptive), and balance tests. Neurological function was graded on a scale from 0 to 18 (normal to maximum deficit).
Tissue preparation and immunohistochemistry
Fifteen days after MCAO, the animals were anesthetized with Zoletil 50 (30 mg/kg) and xylazine (5 mg/kg) and were perfused transcardially with saline followed by 4% paraformaldehyde in 0.1 mol/L phosphate buffer. After perfusion, brains were removed and fixed in a 4% paraformaldehyde solution overnight at 4℃, and they were then placed in a 30% sucrose solution for cryoprotection. Frozen brains were sliced into 20-μm-thick coronal sections using a cryostat vibratome (CM3050S; Leica Microsystems, Wetzlar, Germany), and these sections were stored at -80℃ until further processing.
For immunohistochemistry, tissue sections were treated with 2 N HCl for 30 minutes at 37℃, followed by neutralization with immersion in 0.1 mol/L borate buffer (pH 8.5). Nonspecific binding was blocked by incubating sections with 10% horse serum in phosphate-buffered saline. Sections were then incubated in primary antibodies overnight at 4℃.
The primary antibodies and dilutions used in immunohistochemistry were as follows : ionized calcium-binding adapter molecule 1 (Iba-1; 1 : 400; Wako Chemicals USA, Inc., Dallas, TX, USA), rat endothelial cell antigen-1 (RECA-1; 1 : 400; Bio- Rad Laboratories, Hercules, CA, USA), bromodeoxyuridine (BrdU; 1 : 50; Roche, Basel, Switzerland), and doublecortin (DCX; 1 : 100; Santa Cruz Biotechnology Inc., Dallas, TX, USA). The following secondary antibodies were used: Alexa Fluor 488 anti-mouse IgG (1 : 400; Invitrogen, Waltham, MA, USA), Alexa Fluor 594 anti-goat IgG (1 : 800; Invitrogen), Alexa Fluor 488 anti-rabbit IgG (1 : 400, Invitrogen), and Rhodamine Red-X-conjugated anti-Mouse IgG (1 : 100; Jackson ImmunoResearch Inc., Burlingame, CA, USA). Staining was visualized by a fluorescent microscope (BX61; Olympus Corp., Tokyo, Japan). Immunofluorescence images were acquired using a Zeiss LSM 700 confocal laser microscope (Carl Zeiss, Oberkochen, Germany).
Measurement of cerebral infarction volume
For infarct volume measurement, brain sections were stained with 0.1% cresyl violet (Nissl). Images were acquired using a 4× objective lens under a bright-field microscope (BF53; Olympus). The areas of infarction were quantified using ImageJ software (NIH, Bethesda, MD, USA), and the infarct volume was calculated by multiplying the sum of the infarct area by the distance between sections. After correcting for edema, the infarction volume was calculated as uni follows : Corrected Infarct Volume % = [contralateral hemisphere volume - (ipsilateral hemisphere volume - infarct volume)] / contralateral hemisphere volume × 100.
Quantification and statistics
To count the total number of BrdU- and DCX-positive cells, six sections were obtained at every 280 μm, beginning with a section 1.2 mm rostral to the bregma, and immunohistochemistry and quantification analysis in the subventricular zone (SVZ) were performed to confirm neurogenesis. Iba- 1-positive cells were counted under a fluorescent microscope (BX61; Olympus) in three microscopic fields of the peri-infarct area of each section. RECA-1 positive vessel density was evaluated in images captured from ischemic hemispheres using MetaMorph imaging software (version 7.8.1; Molecular Devices, San Jose, CA, USA). The sum of the values from all six sections was used as the final value.
All data are presented as mean±standard error of the mean. Parametric data were analyzed using one-way analysis of variance, and non-parametric data were analyzed using the Kruskal- Wallis test on ranks, followed by a Mann-Whitney U test. Differences with a p-value <0.05 were deemed statistically significant.
RESULTS
Effects of MFG-E8 on neurobehavioral outcomes
Using the ischemic stroke model, we evaluated the effect of MFG-E8 treatment on the recovery of behavioral functions using the mNSS test. Before MCAO, neurological scores were similar among the experimental and control groups (Fig. 1A). On day 1 after stroke, no treatment×time interactions were detected for any of the mNSS scores, and no significant differences in functional recovery were found between groups. However, as shown in Fig. 1A, lower mNSS mean scores were observed on days 4, 8, 11, and 15 after stroke in the MFG-E8- treated group than in the vehicle group (p<0.05), indicating signif icantly improved neurobehavioral outcomes in MFG-E8-treated rats.
Cerebral infarction volume
Infarcts were found in the cerebral hemisphere ipsilateral to the occlusion in all rats (Fig. 1B and C). The average infarct volumes were 50.6±2.31 mm3 and 51.3±7.43 mm3 in the vehicle and MFG-E8-treated groups, respectively. No significant differences in infarct volumes were found between these two groups (p>0.05).
Immunohistochemical analyses
MFG-E8 inhibits microglial activation in ischemic hemispheres
Immunohistochemical analyses revealed a lower number of Iba-1-positive cells (Fig. 2A) in the peri-infarcted area in the MFG-E8-treated group than in the vehicle group. A significantly lower percentage of hypertrophic or amoeboid Iba- 1-positive cells was also found in the MFG-E8-treated group than in the vehicle group (p<0.001; Fig. 2B). These findings indicate that MCAO-induced accumulation of microglia-positive cells in ischemic brain regions is attenuated by intravenous MFG-E8 treatment, and MFG-E8 suppresses inflammation during the subacute stage of cerebral ischemia.
MFG-E8 enhances angiogenesis in the peri-infarct area in the rat brain
Immunofluorescence staining analyses found a significantly higher number of RECA-1-positive cells in the peri-infarcted area in the MFG-E8-treated group than in the vehicle group (p<0.05) (Fig. 3). The findings support the hypothesis that intravenous MFG-E8 treatment promotes angiogenesis in the peri-infarct area after the subacute stage of cerebral ischemia.
MFG-E8 promotes neurogenesis in the SVZ
Significantly increased BrdU- and DCX-positive cells were found in the SVZ in the MFG-E8 treatment group than in the vehicle treatment group (p<0.001) (Fig. 4). The findings indicate that intravenous MFG-E8 treatment promotes neurogenesis in the injured brain regions after the subacute stage of cerebral ischemia.
There were a significantly lower number of Iba-1-positive cells and higher number of RECA-1 in the peri-infarcted brain region, as well as significantly higher numbers of BrdU- and DCX-positive cells in the subventricular region in the MFG-E8- treated group than in the vehicle group.
DISCUSSION
Our study showed that intravenous MFG-E8 treatment significantly improved neurobehavioral deficits after cerebral ischemia, although it did not have an impact on the infarct volume. Additionally, immunofluorescence staining revealed that MFG-E8-treated animals had a significantly lower number of Iba-1-positive cells and higher number of RECA-1 in the peri-infarcted brain region, as well as significantly higher numbers of BrdU-, and DCX-positive cells in the subventricular region in the MFG-E8-treated group than in the vehicle group. This indicates that MFG-E8 reduces inflammation, promotes angiogenesis, and increases neurogenesis in the ischemia model.
MFG-E8 has an important anti-inflammatory effect that is predicted to be effective in reducing secondary neuronal injury in acute cerebral infarction. Studies have demonstrated that reduced MFG-E8 expression is associated with increased inflammatory response. For instance, MFG-E8 expression was found to be considerably reduced in peritoneal macrophages and RAW264.7 macrophages in which an inflammatory response had been induced by lipopolysaccharide (LPS) treatment [18,19]; the same results were observed in an in vivo animal model of sepsis, and MFG-E8 mRNA expression in the spleen of septic mice decreased after LPS treatment but increased when LPS was administered together with an LPS antagonist, polymyxin-B [24]. In addition, accumulating evidence indicates that increased MFG-E8 inhibits inflammatory responses. For instance, in a co-culture of macrophages and apoptotic cells, MFG-E8 was found to suppress the LPS-mediated inflammatory response by reducing mitogen-activated protein kinases and NF-κB signaling [11,12,17]; moreover, during the LPS-tolllike receptor 4 (TLR4) inf lammatory response induced by the phagocytosis of apoptotic cells, MFG-E8 showed an antiinflammatory effect, and in sepsis and ischemia/reperfusion injury mouse models, MFG-E8 inhibited the LPS-TLR4-mediated inflammatory response by reducing production of inf lammatory cytokines [14,20,21]. Collectively, MFG-E8 inhibits the macrophage-mediated inflammatory response by modulating phagocytosis of apoptotic cells via the LPS-TLR4 pathway, and the activity of intracellular signaling molecules unrelated to phagocytosis. Therefore, we hypothesized that MFG-E8 reduces secondary neuronal injury caused by inf lammatory cytokine activation. In our study, a significant reduction in Iba-1-positive cells was found in the MFG-E8- treated group than in the vehicle group, indicating that MFG-E8 suppresses the inflammatory response in the subacute cerebral infarction rat model.
Additionally, our study demonstrated improved neurobehavioral functional outcomes, as well as increased RECA-1-, BrdU-, and DCX-positive cell numbers, in the MFG-E8 treated group. These results suggest that the reduction in inflammatory response induced by MFG-E8 treatment is associated with increased angiogenesis and neuronal proliferation in the subacute cerebral infarction model. The findings are consistent with those in studies using a similar experimental model of stroke [6,7,10,15,23,25], which indicate the potential of MFG-E8 as a neuroprotective agent to help improve prognosis after acute cerebral infarction.
The present study showed that intravenous MFG-E8 treatment did not reduce the infarct volume but improved functional recovery. In contrast, Cheyuo et al. [5]. found that intravenous administration of exogenous recombinant human MFGE8 (rhMFG-E8) 1 hour after ischemia reduced the infarct size and improved neurological function at both 24 hours and 48 hours after the onset of cerebral ischemia. In addition, histopathological examination showed that rhMFG-E8 treatment protected neurons against necrosis in the penumbra 24 hours after cerebral ischemia onset.
Moreover, studies have found that inflammatory cytokine secretion peaks 24 hours after cerebral ischemia onset, and intravenously injected MFG-E8 does not affect the infarct volume in permanent cerebral ischemia [9]. Therefore, our findings may be attributed to the fact that MFG-E8 was administered during the subacute stage of cerebral infarction 24 hours after MCAO.
There were several limitations to this study. First, the sample size was small and the number of inflammatory cytokines assessed was limited. Second, more categories of experimental infarction groups could have been used. In this experiment, only a 90-minute MCAO group was used; the addition of a 30-minute or 60-minute MCAO group could enable verification of various potential neuroprotective effects of MFG-E8 according to the severity of cerebral infarction. Finally, evaluation of neurological deficits was based solely on a behavioral assessment.
CONCLUSION
Our study indicates that intravenous administration of MFG-E8 improves functional recovery and effectively attenuates inflammatory responses, suggesting that MFG-E8 could be used as a neuroprotective and regenerative treatment during the subacute stage of cerebral infarction. The findings suggest that MFG-E8 improves neurological function by suppressing inf lammation, and increasing angiogenesis and neuronal proliferation during the subacute stage of cerebral ischemia. Further studies with a larger sample size are needed to confirm our findings.
PubReader
ePub Link
XML Download
Full text via DOI
Download Citation 
Print 
